What is the manufacturer of avatrombopag (Sucoxin)?

Avatrombopag is an important drug primarily used to treat thrombocytopenia associated with chronic liver disease. The original drug of avatrombopag is produced by Eisai Co., Ltd. of Kawashima Plant in Japan. The company has strong R&D capabilities and a strict quality control system to ensure the efficacy and safety of the drugs.

Avatrombopag is an oral small-molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation, thereby reducing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require platelet transfusions before surgery to reduce the risk of bleeding. Thrombocytopenia is a common complication in patients with chronic liver disease, caused by liver disease or interferon-based antiviral therapy.

Avatrombopag is the world's first oral thrombopoietin receptor agonist (TPO-RA) approved by the U.S. Food and Drug Administration (FDA) for the treatment of thrombocytopenia associated with chronic liver disease (CLD). It can effectively increase platelet count, meet the needs of patients for surgery or diagnostic procedures, and reduce the risk of bleeding.

Su Kexin has been included in the national medical insurance directory, which has greatly reduced the financial burden on patients and enabled more patients to benefit from this innovative drug. Since its launch, Sukesin has achieved rapid growth in the domestic market with its remarkable efficacy and safety, becoming an important treatment option for patients with thrombocytopenia.

In summary, avatrombopag is an innovative drug produced by Eisai Co., Ltd. of Kawashima Plant in Japan. The drug has excellent performance in the treatment of thrombocytopenia associated with chronic liver disease and has been widely recognized by patients and doctors.